Atlas market file · Equity · United States
Damora Therapeutics, Inc.DMRA
- Last close
- 29.92
- Change
- +0.13%
- 96-bar range
- 17.655 – 34.89
- As of
- 7 Aug 2026
Damora Therapeutics, Inc. is a pharmaceutical preparations issuer listed as DMRA on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
DMRA
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+121.63% over the window).
Source rail: Yahoo Finance chart API (DMRA). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for DMRA. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
DMRA public profile
Pharmaceutical preparations issuer. Damora Therapeutics, Inc. is connected to current market context, cited company sources and its retained research file.
Damora Therapeutics, Inc. trades as DMRA on NASDAQ. Damora Therapeutics, Inc. (DMRA) has a latest verified close of 29.92, up 0.13%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files DMRA under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Damora Therapeutics, Inc. today
Damora Therapeutics (DMRA) kicked off July with a press release touting its mission to 'fundamentally redefine care for people with hematologic disorders'-a claim backed by $1.5 billion in global capital raised and the commercial launch of AYVAKIT® (avapritinib). Yet the company’s latest 10-Q filing reveals a starkly different narrative: a $27.8 million net loss and $30.8 million operating loss for the quarter ended March 31, 2026, despite holding $532.9 million in cash reserves. (source: SEC EDGAR 10-Q, period ending 2026-03-31)
DMRA’s official product page and corporate messaging emphasize 'innovative R&D in allergy/inflammation, oncology, and rare disease,' but the numbers suggest caution. Research and development expenses consumed $23.8 million during the period, while diluted earnings per share sank to -$0.62. The company’s 34.3 million diluted shares outstanding underscore a reliance on equity issuance, even as insiders have filed multiple 8-Ks disclosing share transfers and governance updates. (source: SEC EDGAR 10-Q, period ending 2026-03-31)
Recent filings include an 8-K on July 20, 2026, disclosing material changes in operations, and a June 22 144 filing detailing restricted stock awards. While the company maintains $535.4 million in total assets against just $23.8 million in liabilities, its negative operating cash flow of $20.6 million raises questions about sustainability. The market will watch whether DMRA’s pipeline can convert cash into revenue before the balance sheet starts demanding a return. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1800315)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
DMRA technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on DMRA
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep DMRA research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
DMRA FAQ
What is Damora Therapeutics, Inc. (DMRA)?Damora Therapeutics, Inc. (DMRA) has a latest verified close of 29.92, up 0.13%, dated 7 Aug 2026. Use this page to check the price chart, company context,...
Damora Therapeutics, Inc. (DMRA) has a latest verified close of 29.92, up 0.13%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for DMRA?Damora Therapeutics, Inc. (DMRA) has a latest verified close of 29.92, up 0.13%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources,...
Damora Therapeutics, Inc. (DMRA) has a latest verified close of 29.92, up 0.13%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files DMRA under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the DMRA page updated?The DMRA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The DMRA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for DMRA?The DMRA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:DMRA. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The DMRA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:DMRA. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on DMRA?Yes. The workstation can open DMRA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open DMRA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this DMRA page investment advice?No. The DMRA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The DMRA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →